Articles

Zynerba Pharmaceuticals Announces Top Line Results from ZYN001 THC-Prodrug Patch Phase 1 Study

CORRECTION FIT Biotech Oy: FIT Biotech\'s company site has been launched in Inderes.fi

Cue Health Receives ISO 13485 Certification

NEOVACS

GEVO...ça repart

Globus Medical Adds Two Innovative Solutions to Growing Trauma Portfolio

Antibe Therapeutics Releases Secondary Endpoint Data from Recent Phase 2B Gastrointestinal Safety Study for Lead Drug, ATB-346 | Business Wire

Poxel Announces Completion of Patient Enrollment for TIMES 1 Trial in the Phase 3 Registration Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan | Business Wire

FIT Biotech Oy: FIT Biotech webcasts the company half-year financial report on September 6th 2018, at 10.00 AM.

Antibe Therapeutics Reports 2018 Year-End Financial and Operating Results | Business Wire

Alteogen and Lynkogen Enter into an Exclusive Option Agreement to Develop Proprietary Fusion Proteins for the Treatment of NASH and Metabolic Diseases | Business Wire